- Home
- CIFR vs ANIP Comparison
CIFR vs ANIP Comparison
Compare CIFR & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- ANIP
- Stock Information
- Founded
- CIFR 2021
- ANIP 2001
- Country
- CIFR United States
- ANIP United States
- Employees
- CIFR N/A
- ANIP N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- ANIP Health Care
- Exchange
- CIFR Nasdaq
- ANIP Nasdaq
- Market Cap
- CIFR 2.1B
- ANIP 2.0B
- IPO Year
- CIFR N/A
- ANIP N/A
- Fundamental
- Price
- CIFR $10.85
- ANIP $97.71
- Analyst Decision
- CIFR Strong Buy
- ANIP Strong Buy
- Analyst Count
- CIFR 10
- ANIP 9
- Target Price
- CIFR $7.63
- ANIP $86.00
- AVG Volume (30 Days)
- CIFR 36.0M
- ANIP 475.8K
- Earning Date
- CIFR 10-30-2025
- ANIP 11-07-2025
- Dividend Yield
- CIFR N/A
- ANIP N/A
- EPS Growth
- CIFR N/A
- ANIP N/A
- EPS
- CIFR N/A
- ANIP N/A
- Revenue
- CIFR $158,849,000.00
- ANIP $747,399,000.00
- Revenue This Year
- CIFR $86.84
- ANIP $39.32
- Revenue Next Year
- CIFR $70.70
- ANIP $9.62
- P/E Ratio
- CIFR N/A
- ANIP N/A
- Revenue Growth
- CIFR 0.11
- ANIP 38.68
- 52 Week Low
- CIFR $1.86
- ANIP $52.50
- 52 Week High
- CIFR $10.92
- ANIP $99.50
- Technical
- Relative Strength Index (RSI)
- CIFR 78.50
- ANIP 75.51
- Support Level
- CIFR $7.08
- ANIP $96.50
- Resistance Level
- CIFR $8.78
- ANIP $99.50
- Average True Range (ATR)
- CIFR 0.91
- ANIP 2.17
- MACD
- CIFR 0.35
- ANIP -0.36
- Stochastic Oscillator
- CIFR 98.47
- ANIP 81.77
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.